A previous study reported that the activation of the TGF-β/SMAD signaling pathway may promote tumor progression in multiple types of human cancer, including gastric cancer, hepatocellular carcinoma, and bladder cancer [21–23]. This evidence concerns the gene TGFB1 and urinary bladder carcinoma.